Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women's Health Inc. (AWH) delivers innovative diagnostic solutions for gynecologic diseases through its AI-powered blood tests. This comprehensive news hub provides investors and healthcare professionals with essential updates on the company's advancements in ovarian cancer risk assessment and women's health diagnostics.
Access timely reports on regulatory milestones, clinical study results, and financial performance. Our curated collection includes press releases about OvaWatch developments, partnership announcements with medical institutions, and analyses of emerging trends in precision diagnostics.
Key content categories cover earnings reports, product innovation updates, strategic collaborations, and peer-reviewed research validations. Each update maintains clinical context while focusing on business implications for informed decision-making.
Bookmark this page for centralized access to Aspira's evolving diagnostic portfolio and market-moving announcements. Check regularly for objective reporting on developments impacting women's healthcare and diagnostic technology sectors.
Aspira Women's Health (NASDAQ:AWH) has announced the closing of a $1.37 million private placement of Senior Secured Convertible Promissory Notes due March 6, 2030. The notes, sold to existing and new accredited investors, will accrue interest at 3.34% payable quarterly.
The Convertible Notes can be converted into units comprising one share of common stock and 2.25 warrants at $0.25 per unit. The warrants are exercisable for five years at $0.50 per share, with an option to exercise at $0.25 per share between months 6-24 after issuance. The company maintains the right to convert the notes if total gross proceeds from sales reach $4 million.
The proceeds will support Aspira's ongoing commercial activities, general corporate purposes, and working capital. The securities sold in this private placement are not registered under the Securities Act of 1933.
Aspira Women's Health (NASDAQ:AWH) has announced the withdrawal of its Form S-1 Registration Statement (No. 333-284182) with the Securities and Exchange Commission (SEC). The Registration Statement, initially filed on January 8, 2025, was intended for a public offering. The company confirmed that the Registration Statement was never declared effective by the SEC, and no securities were sold in connection with the proposed offering.
The company, which focuses on developing gynecologic disease diagnostic tools, has decided not to pursue the public offering at this time. This announcement does not constitute an offer to sell or solicitation to buy the company's common stock or other securities.
Aspira Women's Health (NASDAQ:AWH) has announced the appointment of Ellen Beausang to its Board of Directors, effective February 10, 2025. Beausang, who currently serves as Chief Commercial Officer at BioReference Health, brings extensive experience in commercial strategy development within the diagnostics sector. The appointment comes at what the company describes as a commercial inflection point, as it focuses on growing existing business lines and developing new diagnostic tests to expand market opportunities.
Beausang's background includes over 5 years at BioReference Health and previous executive positions at major healthcare companies including Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics. CEO Michael Buhle highlighted her expertise as valuable for accelerating business growth and advancing the company's mission in women's healthcare.
Aspira Women's Health (AWH) has announced key leadership changes. Mike Buhle has been appointed as SVP of Commercial Operations, bringing over 25 years of experience in driving commercial growth and new product launches in diagnostics and life science tools. Buhle previously served as Chief Commercial Officer at Biovision Diagnostics and VP of Sales, Americas for Congenica.
Additionally, Interim CFO John Kallassy will depart on January 10, 2025. The company has retained James O'Brien as CFO advisor, who brings 30+ years of experience in biotechnology, pharmaceutical, and medical device industries. O'Brien, founder of Great Island Advisors , previously served as CFO of Faron Pharmaceuticals and Cognition Therapeutics.
Both Buhle and O'Brien will join interim CEO Dr. Sandra Milligan for meetings during the JP Morgan Healthcare Conference week starting January 13th in San Francisco.
Aspira Women's Health (NASDAQ: AWH) announced that CEO Nicole Sandford will step down immediately for personal reasons, with Dr. Sandra Milligan, the company's President, appointed as interim CEO. During Sandford's tenure, the company launched the OvaWatch multivariate assay for ovarian cancer detection and received a $10 million award from the Advanced Research Projects Agency for Health to complete their endometriosis detection product. Sandford will remain as a consultant to ensure a smooth transition while the company conducts a nationwide search for a permanent CEO. The Board praised Sandford's contributions in stabilizing the business and building a strong team for future growth.
Aspira Women's Health (AWH) has achieved the first milestone of its ARPA-H Sprint for Women's Health Award, receiving a $2 million payment from the total $10 million grant. The funding supports the development of a multi-marker blood test for endometriosis detection, utilizing AI-enabled algorithms combining protein and microRNA biomarkers. The first milestone included project execution plans, risk mitigation strategies, and laboratory expansion activities. The company expects to complete the second milestone in Q1 2025, which focuses on R&D capabilities expansion and will result in a $1.5 million payment upon completion.
Aspira Women's Health reported Q3 2024 financial results with OvaSuite revenue of $2.3 million, representing a 2% increase year-over-year. Test volume grew 4% to 6,001 units, driven by OvaWatch's 27% growth. The company maintained a 60% gross profit margin and reduced cash utilization to $2.9 million, down 12% from Q2. Notably, Aspira secured a $10 million ARPA-H contract for ENDOinform development. The company reaffirmed its full-year 2024 cash utilization guidance of $13.0-$14.5 million.
Aspira Women's Health has expanded its co-marketing and distribution collaboration with BioReference to include OvaWatch® in their portfolio. The partnership, which has included Ova1Plus® since 2022, will now market Aspira's complete OvaSuite portfolio to BioReference's healthcare provider clients. This expansion follows OvaWatch's approval by the New York State Department of Health's Clinical Laboratory Evaluation Program, making it available to over 15 million women in New York and New Jersey.
Aspira Women's Health (Nasdaq: AWH) has scheduled its Q3 2024 earnings release for Thursday, November 14, 2024. The company will discuss financial results for the three and nine months ended September 30, 2024. Management will host a conference call at 8:30 am ET to present financial results and provide a corporate update. The call will be accessible via toll-free number (877-545-0320) and international number (973-528-0002) with access code 436613. A webcast replay will be available on the company's Investor Relations website.
Aspira Women's Health (Nasdaq: AWH) announced it has been awarded $10 million over two years from the Advanced Research Projects Agency for Health (ARPA-H) as part of the Sprint for Women's Health initiative. The funding will support the development of ENDOinform™, a multi-marker blood test for endometriosis detection using AI-enabled algorithms combining protein and microRNA biomarkers. Selected as one of 23 awardees from over 1,700 submissions, Aspira received one of only six Launchpad awards for advanced-stage projects. The company expects to meet its first milestone in Q4 2024, triggering a $2 million payment. The company will host a virtual R&D Day on October 29, 2024, to discuss the development pipeline.
FAQ
What is the current stock price of Aspira Women`s Health (AWH)?
What is the market cap of Aspira Women`s Health (AWH)?
